Clusterin Human ELISA

Catalog number: RD194034200R
Brand: BioVendor
Packing: 96 wells
Price: € 510.00
Expected delivery time: 7 days

Product specifications for - Clusterin Human ELISA

Product group: Assays
Category: ELISA / EIA
Molecular weight: 75 - 80 kDa
Assay Sensitivity: 0,5 ng/ml
Assay Precision: Inter assay: n = 8, CV = 7,8%, Intra assay: n = 8, CV = 6,2%,
Assay Sample Type: serum, plasma, cerebrospinal fluid (CSF), urine, cell culture, and cell lysate
Assay Time: The total assay time is less than 3.5 hours.
Assay Detection Range: 5 - 160 ng/ml
  Research Use Only
UNSPSC: 41116158
Storage instructions: Store the complete kit at 2-8-¦C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Scientific information: 
Scientific info: Clusterin (Apolippoprotein J, SP-40,40, TRPM-2, SGP-2, pADHC-9, CLJ, T64, GP III, XIP8) is a highly conserved disulfide-linked secreted heterodimeric glycoprotein of 75-80 kDa but truncated forms targeted to the nucleus have also been identified. The protein is constitutively secreted by a number of cell types including epithelial and neuronal cells and is a major protein in physiological fluids including plasma, milk, urine, cerebrospinal fluid and semen. Due to its wide breath of tissue distribution many diverse physiological functions have been attributed to Clusterin including sperm maturation, membrane recycling, lipid transportation, tissue remodelling, complement inhibition and cell-cell or cell-substratum interactions. Moreover, it was proposed that Clusterin functions as an extracellular chaperon that stabilizes stressed proteins in a folding-competent state, and that the protein is involved in programmed cell death. Another defining prominent function of Clusterin is its induction in many severe physiological disturbances states including kidney degenerative diseases, prostate and vesicle carcinogenesis, ovarian cancer and several neurodegenerative conditions (Alzheimer s disease). Recent study demonstrates, that serum Clusterin level increases significantly in diabetic type II patients and in patients with developing coronary heart disease, or myocardial infarction. These data raise the possibility that elevated Clusterin levels in serum may represent a strong indication of vascular damage. In patients with systemic lupus erythematosus (SLE), reduced serum Clusterin levels correlated inversely with disease activity. Lowered Clusterin levels could be involved in the pathogeneses of SLE on account of decreased protective effects. Another interesting observation obtained in rat model suggests that measurement of urinary Clusterin levels may be a useful clinical marker for the severity of renal tubular damage. Furthermore, urinary Clusterin may also help to differentiate between tubular and glomerular forms of proteinuria. Areas of investigation: Coronary heart diseases, Myocardial infarction, Neurodegenerative diseases, Kidney degenerative disease, Renal tubular damage
Additional information: 
Synonyms: RD194034200R; BioVendor
Aguilar-Mahecha A, Cantin C, O'Connor-McCourt M, Nantel A, Basik M. Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker. Proteome Sci. 2009,7:15 Read more
Banfi C, Parolari A, Brioschi M, Barcella S, Loardi C, Centenaro C, Alamanni F, Mussoni L, Tremoli E. Proteomic analysis of plasma from patients undergoing coronary artery bypass grafting reveals a protease/antiprotease imbalance in favor of the serpin alpha1-antichymotrypsin. J Proteome Res. 2010 May 7,9 (5):2347-57 Read more
Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Sep 20,28 (27):4247-54 Read more
Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res. 2009 Jan 15,15 (2):708-13 Read more
Cubedo J, Padro T, Garcia-Moll X, Pinto X, Cinca J, Badimon L. Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction. J Proteome Res. 2011 Jan 7,10 (1):211-20 Read more
Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007 Jul,6 (7):2833-40 Read more
Dukic L, Simundic AM, Martinic-Popovic I, Kackov S, Diamandis A, Begcevic I, Diamandis EP. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. Clin Biochem. 2016 Feb,49 (3):213-8 Read more
Flehmig G, Scholz M, Kloting N, Fasshauer M, Tonjes A, Stumvoll M, Youn BS, Bluher M. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS One. 2014,9 (6):e99785 Read more
Garcia-Rodriguez S, Arias-Santiago S, Perandres-Lopez R, Orgaz-Molina J, Castellote L, Buendia-Eisman A, Ruiz JC, Naranjo R, Navarro P, Sancho J, Zubiaur M. Decreased plasma levels of clusterin in patients with psoriasis. Actas Dermosifiliogr. 2013 Jul-Aug,104 (6):497-503 Read more
Holzer M, Trieb M, Konya V, Wadsack C, Heinemann A, Marsche G. Aging affects high-density lipoprotein composition and function. Biochim Biophys Acta. 2013 Sep,1831 (9):1442-8 Read more